Zonisamide sodium_product_DataBase

Bioactivity	Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy[1][2][3][4].
Invitro	Zonisamide sodium (10, 50, 100, 200 µM; 24 h) increases viability of SH-SY5Y cells via an anti-apoptotic effect[1].Zonisamide sodium (100 µM; 24 h) shows neuroprotective effects in PD-cellular models. (PD: parkinson’s disease)[1].Zonisamide sodium (100 µM; 24 h) reduces levels of proapoptotic molecules, and upregulates levels of MnSOD (MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis)[1].Zonisamide sodium (0.1, 0.3, 1 μM; 24 h) inhibits cardiac hypertrophy and fibrosis in vitro[3].Zonisamide sodium markedly increases the expression of Hrd1 in Ang II-treated NRCMs[3]. Cell Viability Assay[1] Cell Line:
Name	Zonisamide sodium
CAS	68291-98-5
Formula	C8H7N2NaO3S
Molar Mass	234.21
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

PeptideDB